2025-10-17 - Analysis Report
Okay, here's a report analyzing TG Therapeutics Inc. (TGTX) based on the provided data.

## TG Therapeutics Inc. (TGTX) Analysis

**Company Overview:** TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

### 1. Performance vs. S&P 500 (VOO)

*   **TGTX Cumulative Return:** 80.12%
*   **VOO Cumulative Return:** 96.43%
*   **Absolute Divergence (Current):** -16.31% (TGTX underperforming VOO)
*   **Relative Divergence:** 20.0 (Indicates the current divergence is in the lower range of its historical divergence.)

**Analysis:** TGTX has underperformed the S&P 500 over the analyzed period. The relative divergence suggests that the current underperformance is relatively close to the best underperformance that it showed in the past.

**Alpha, Beta Analysis Table:**

| Year       | CAGR   | MDD   | Alpha   | Beta   | Cap(B) |
|------------|--------|-------|---------|--------|--------|
| 2015-2017  | -5.0%  | 73.5% | -33.0%  | -0.0   | 1.3    |
| 2016-2018  | -12.0% | 73.5% | -27.0%  | -0.0   | 0.7    |
| 2017-2019  | 74.0%  | 74.1% | 52.0%   | 0.0    | 1.8    |
| 2018-2020  | 316.0% | 74.1% | 293.0%  | 0.1    | 8.4    |
| 2019-2021  | 124.0% | 74.1% | 78.0%   | 0.3    | 3.1    |
| 2020-2022  | -71.0% | 77.8% | -71.0%  | -0.0   | 1.9    |
| 2021-2023  | -284.0%| 77.8% | -285.0% | -1.1   | 2.8    |
| 2022-2024  | 56.0%  | 77.8% | 36.0%   | -1.0   | 4.9    |
| 2023-2025  | 80.0%  | 74.8% | 20.0%   | -0.1   | 5.5    |

**Analysis:**

*   **CAGR:** Fluctuates significantly, indicating high volatility.  Periods of strong growth are followed by sharp declines.
*   **MDD:** Consistently high Maximum Drawdown, suggesting substantial risk.
*   **Alpha:**  Shows periods of outperformance (positive Alpha) and significant underperformance (negative Alpha) relative to the market.
*   **Beta:** Generally low, but negative in recent periods, suggesting an inverse relationship with the market (TGTX moves opposite to the market).

### 2. Recent Price Action

*   **Current Price:** 34.14
*   **Last Market Data:** Price: 34.87, Previous Close: 35.05, Change: -0.51
*   **5-Day Moving Average:** 34.37
*   **20-Day Moving Average:** 35.04
*   **60-Day Moving Average:** 32.36

**Analysis:** The price is currently below both the 5-day and 20-day moving averages but above the 60-day moving average.  The recent price decrease (-0.51) and the fact that the 5-day MA is below the 20-day MA suggest a short-term downward trend.

### 3. Technical Indicators & Market Risk

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 40.93 (Neutral, not oversold or overbought)
*   **PPO:** -1.12 (Negative, suggesting a potential downtrend)
*   **Hybrid Signal:** Buy 100% of cash (27 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Delta_Previous_Relative_Divergence:** -3.6 (Short-term decrease in relative divergence, indicating short-term underperformance relative to the benchmark)
*   **Expected Return:** -115.8% (Projected underperformance compared to S&P 500 over a 2+ year investment horizon)

**Analysis:** The MRI indicates a medium investment risk. The RSI is neutral. The negative PPO and the negative Delta_Previous_Relative_Divergence support the recent downward price action. The Hybrid signal suggests a bullish signal. The significantly negative expected return is a major concern. The recent price change of -0.51 suggests a downward pressure.

### 4. Recent News & Events

*   **Positive News:** Multiple news articles highlight positive 6-year safety and efficacy data for BRIUMVI in multiple sclerosis patients, showing a high percentage free from disease progression. Institutional investors are rewarded for their bets after a market cap gain.
*   **Neuraxpharm Participation:** Neuraxpharm's involvement in ECTRIMS reinforces commitment to multiple sclerosis.

**Analysis:** The recent news is predominantly positive, focusing on the long-term efficacy and safety of TG Therapeutics' BRIUMVI drug for multiple sclerosis. This could be a positive catalyst for the stock in the long term.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean Rating: 1.78)
*   **Target Price:** Average: 43.57, High: 60.00, Low: 11.00
*   **Recent Rating Changes:** No changes are listed.

**Analysis:** Analyst consensus is positive ("Buy"), and the average target price suggests significant upside potential. However, the wide range between the high and low target prices (11.00 to 60.00) indicates considerable uncertainty among analysts.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue     |
|------------|------|-------------|
| 2025-08-08 | 0.19 | 0.14 B$     |
| 2025-05-09 | 0.03 | 0.12 B$     |
| 2024-11-07 | 0.03 | 0.08 B$     |
| 2024-08-09 | 0.05 | 0.07 B$     |
| 2025-08-08 | 0.05 | 0.07 B$     |

**Analysis:**  The recent earnings data shows positive EPS and increasing revenue, especially in the most recent quarter (2025-08-08). This suggests improving financial performance.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-06-30 | $0.14B   | 86.58%        |
| 2025-03-31 | $0.12B   | 87.14%        |
| 2024-12-31 | $0.11B   | 85.77%        |
| 2024-09-30 | $0.08B   | 88.86%        |
| 2024-06-30 | $0.07B   | 88.70%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE      |
|------------|----------|----------|
| 2025-06-30 | $0.28B   | 10.20%   |
| 2025-03-31 | $0.24B   | 2.13%    |
| 2024-12-31 | $0.22B   | 10.49%   |
| 2024-09-30 | $0.19B   | 2.02%    |
| 2024-06-30 | $0.18B   | 3.87%    |

**Analysis:**  Revenue is trending upwards, and profit margins are exceptionally high. Equity is also increasing, indicating a strengthening financial position. ROE fluctuates but is generally positive.

### 7. Overall Summary

TG Therapeutics (TGTX) presents a mixed picture.

*   **Positives:**
    *   Strong revenue growth and high profit margins.
    *   Positive clinical trial data for BRIUMVI, a key product.
    *   "Buy" analyst consensus with significant upside potential (average target price).
    *   The Hybrid Signal is bullish
*   **Negatives:**
    *   Historical underperformance compared to the S&P 500.
    *   High historical volatility and maximum drawdown.
    *   Negative expected return (significant underperformance projected).
    *   Recent short-term price weakness.

**Conclusion:**

TGTX is a high-risk, high-reward stock.  The positive clinical data and improving financials are encouraging, but the historical volatility and negative expected return are significant concerns.  The analyst consensus suggests the market sees potential, but the wide range in target prices highlights the uncertainty. Investors should carefully weigh their risk tolerance and conduct further due diligence before investing. Monitoring upcoming earnings reports and news related to BRIUMVI will be critical.
